

Eradication of HIV by T cell immunotherapy

Jason T. Kimata, PhD
Baylor College of Medicine

From Research to the Real World: Sharing Science Symposium
September 5, 2018

Why We Did this Study


- The Problem: Antiretroviral therapy inhibits HIV replication and drives down the level of virus in the body, but does not cure infection.
- The Reason: HIV can persist in CD4+ T cells in a silent state, or in protected sites within the body, and escapes the host immune response.
- The Question: How can we help improve the immune response against HIV?
- The Idea: Create HIV-specific killer T cells (CD4+ and CD8+) capable of preventing HIV infection and destroying the infected cells.

What We Did


- We developed a cell-associated HIV inhibitor that can protect CD4+ T cells from infection
- Developed a method to expand HIV-specific killer T cells from infected individuals
- Used the inhibitor to genetically modify HIV-specific killer T cells
- Examined the ability of these killer cells to eradicate HIV infected cells

What We Found

I. Potent inhibition of HIV infection by a cell-anchored inhibitor




2. Protects neighboring cells from infection



What We Found

II. Eradication of HIV-infected cells



What Our Results Mean and Why this Matters

- It is possible to overcome the resistance of HIV-producing cells to killer T cells by combining the activities of:
 - i) an anti-cancer drug that prevents cell survival, and primes HIV-producing cells to die
 - ii) genetically-modified HIV-killer T cells
- Immune restoration with genetically modified HIV-specific killer T cells may be a feasible way to eliminate infected cells, even in the absence of antiretroviral therapy.


Acknowledgments

Supported by NIH

P30 AI036211

R01 AI106574

R33 AI116167



Kimata Lab

Reetakshi Arora

Emile Gleeson

Cesar Lopez

Anisha Misra

Hongmei Ruan

Monica Yu Kimata



National Children's

Catherine Bollard

C. Russell Cruz

Shabnum Patel

Pasteur-Shanghai

Paul Zhou

Lihong Liu

Weiming Wang

Michael Wen

GWU

Brad Jones

